疫苗接种对中国传染病防控事业的巨大贡献

刘元宝; 江湖大川; 李靖欣; 吴莹; 朱凤才

doi:10.16462/j.cnki.zhjbkz.2019.08.002

疫苗接种对中国传染病防控事业的巨大贡献

doi: 10.16462/j.cnki.zhjbkz.2019.08.002

1.
210009 南京, 江苏省疾病预防控制中心免疫规划所
2.
210009 南京, 江苏省疾病预防控制中心疫苗临床评价所
3.
210009 南京, 江苏省疾病预防控制中心急性传染病防制所
4.
210009 南京, 国家卫生健康委员会肠道病原微生物重点实验室, 南京医科大学全球健康中心

详细信息

作者简介:
朱凤才, 主任医师, 博士生导师, 江苏省疾病预防控制中心副主任。江苏省"333工程"第一层次培养对象, 入选"国家百千万人才工程", 先后获得国家人事部、卫计委和江苏省"有突出贡献中青年专家"、"全国优秀科技工作者"等荣誉称号, 享受国务院政府特殊津贴。首届国家免疫规划专家咨询委员会委员, 中华预防医学会旅行卫生专业委员会第四届委员会副主任委员, 第十一届药典委员会委员, 中国微生物学会人兽共患病病原学专业委员会副主任委员

通讯作者:
朱凤才. E-mail: jszfc@vip.sina.com

中图分类号: R186
计量
- 文章访问数: 444
- HTML全文浏览量: 294
- PDF下载量: 63
- 被引次数: 0
出版历程
- 收稿日期: 2019-06-15
- 刊出日期: 2019-08-10

The great contribution of vaccination to the prevention and control of communicable diseases in China

1.
Department of Expanded Program on Immunization, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China
2.
Department of Vaccine Clinical Evaluation, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China
3.
Department of Acute Infectious Disease Control, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing 210009, China
4.
Jiangsu Provincial Center for Disease Control and Prevention, Key Laboratory of Intestinal Pathogenic Microorganisms of National Health Commission, Global Health Center of Nanjing Medical University, Nanjing 210009, China

More Information

Corresponding author: ZHU Feng-cai. E-mail: jszfc@vip.sina.com

摘要

摘要: 新中国成立70年来，我国公共卫生事业特别是传染病防控取得了举世瞩目的成就，这与疫苗接种密不可分。本文旨在对我国免疫规划疫苗和创新疫苗的应用发展进行概括和梳理，列举脊髓灰质炎疫苗、乙型肝炎疫苗、百白破疫苗、麻疹疫苗和甲型肝炎疫苗等在我国传染病防控方面70年来的成就和突出贡献。回顾近年来我国在创新疫苗研发上的重大突破，为今后我国计划免疫的发展提供思路和线索。
- 传染病 /
- 疫苗 /
- 免疫接种规划 /
- 进展 /
- 成就 /
- 公共卫生
Abstract: During the past 70 years since the founding of New China, Chinese public health especially the prevention and control of infectious diseases have made remarkable achievements, which benefited from the vaccination. This study is to summarize the progress of immunization and vaccines, the achievements and contributions of vaccines including polio vaccine, hepatitis B vaccine, diphtheria, tetanus and acellular pertussis combined vaccine, measles vaccine and hepatitis A vaccine to the prevention and control of infectious diseases in China in the past 70 years and to review the research and development of innovative vaccines in China in recent years, which may provide clues for the development of the expanded programe on immunization in China in the future.
- Communicable diseases /
- Vaccines /
- Immunization Programs /
- Progress /
- Achivements /
- Public health

HTML全文

参考文献(15)

[1]	刁连东, 孙晓东. 实用疫苗学[M]. 上海: 上海科学技术出版社, 2015. Diao LD, Sun XD. Practical vaccineology[M]. Shanghai: Shanghai Science and Technology Press, 2015.
[2]	WHO. Polio vaccines: WHO position paper, January 2014[J]. Wkly Epidemiol Rec, 2014, 89: 73-92. http://www.ncbi.nlm.nih.gov/pubmed/24707513
[3]	王贵强, 王福生, 成军, 等. 慢性乙型肝炎防治指南(2015年版)[J]. 中华实验和临床感染病杂志(电子版), 2015, 9(5): 570-589. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSGR201505001.htm Wang GQ, Wang FS, Cheng J, et al. Guidelines for the prevention and treatment of chronic hepatitis B (2015 edition)[J]. Chinese Journal of Experimental and Clinical Infectious Diseases (electronic edition), 2015, 9(5): 570-589. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSGR201505001.htm
[4]	Cui FQ, Liang XF, Wang FZ, et al. Development, production, and postmarketing surveillance of Hepatitis A vaccines in China[J]. J Epidemiol, 2014, 24(3): 169-177. DOI: 10.2188/jea.je20130022.
[5]	Zhu F, Xu W, Xia J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China[J]. N Engl J Med, 2014, 370(9): 818-828. DOI: 10.1056/NEJMoa1304923.
[6]	Zhu FC, Liang ZL, Li XL, et al. Immunogenicity and safety of an enterovirus 71 vaccine in healthy Chinese children and infants: a randomised, double-blind, placebo-controlled phase 2 clinical trial[J]. Lancet, 2013, 381(9871): 1037-1045. DOI: 10.1016/S0140-6736(12)61764-4.
[7]	Zhu FC, Meng FY, Li JX, et al. Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet, 2013, 381(9882): 2024-2032. DOI: 10.1016/S0140-6736(13)61049-1.
[8]	Dalton HR, Bendall R, Ijaz S, et al. Hepatitis E: an emerging infection in developed countries[J]. Lancet Infect Dis, 2008, 8(11): 698-709. DOI: 10.1016/S1473-3099(08)70255-X.
[9]	Zhu FC, Zhang J, Zhang XF, et al. Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial[J]. Lancet, 2010, 376(9744): 895-902. DOI: 10.1016/S0140-6736(10)61030-6.
[10]	WHO. New influenza A (H1N1) virus: global epidemiological situation, June 2009[J]. Wkly Epidemiol Rec, 2009, 84(25): 249-257. http://www.bmj.com/lookup/external-ref?access_num=19537358&link_type=MED&atom=%2Fbmj%2F343%2Fbmj.d5956.atom
[11]	Zhu FC, Wang H, Fang HH, et al. A novel influenza A (H1N1) vaccine in various age group[J]. N Engl J Med, 2009, 361(25): 2414-2423. DOI: 10.1056/NEJMoa0908535.
[12]	Liang XF, Wang HQ, Wang JZ, et al. Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial[J]. Lancet, 2010, 375(9708): 56-66. DOI: 10.1016/S0140-6736(09)62003-1.
[13]	Cenciarelli O, Pietropaoli S, Malizia A, et al. Ebola virus disease 2013-2014 outbreak in west Africa: an analysis of the epidemic spread and response[J]. Int J Microbiol, 2015, (2015): 769121. DOI: 10.1155/2015/7.
[14]	Gatherer D. The 2014 Ebola virus disease outbreak in West Africa[J]. J Gen Virol, 2014, 95(8): 1619-1624. DOI: 10.1099/vir.0.067199-0.
[15]	Zhu FC, Wurie AH, Hou LH, et al. Safety and immunogenicity of a recombinant adenovirus type-5 vector-based Ebola vaccine in healthy adults in Sierra Leone: a single-centre, randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet, 2017, 389(10069): 621-628. DOI: 10.1016/S0140-6736(16)32617-4.